SEC Form 4 · accession 0000880771-15-000051
SCICLONE PHARMACEUTICALS INC · SCLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Hong Zhao
Officer — CEO, China Operations
Period of report
Apr 3, 2015
Accepted (ET)
Apr 7, 2015 · 4:13 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000880771
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF1,F2,F3 | — | Apr 3, 2015 | A | 75,000 | A | — | — | Common Stock | 75,000 | 124,500 | D |
Explanation of responses
- F1Granted under the Issuer's 2005 Equity Incentive Plan.
- F2Each restricted stock unit represents the contingent right to receive one share of SciClone Pharmaceuticals, Inc.'s common stock.
- F3Vesting to be in three equal annual installments at the close of business on the first business day following December 31 of each of calendar year 2015, 2016, and 2017, provided that the Participant's service with the Company has not terminated prior to the applicable vesting time.